public.fnol.cz - /PS/Komise/Eticka/nové studie CTIS 2024/čj. 117 - SÚKL č. 1162/Part I/

[To Parent Directory]

10/21/2024  1:07 PM       170915 B1_Cover letter_2024-515689-15.PDF
10/21/2024  1:08 PM       510036 D1_Protocol synopsis_CZ_2024-515689-15-00_Redacted.PDF
10/21/2024  1:08 PM       229300 D1_Protocol synopsis_CZ_2024-515689-15-00_Unapplied.PDF
10/21/2024  1:08 PM       455544 D1_Protocol Synopsis_ENG_2024-515689-15_Redacted.PDF
10/21/2024  1:08 PM       457043 D1_Protocol Synopsis_ENG_2024-515689-15_Unapplied.PDF
10/21/2024  1:08 PM       287257 D1_Protocol synopsis_RO_2024-515689-15_Redacted.PDF
10/21/2024  1:08 PM       185144 D1_Protocol synopsis_RO_2024-515689-15_unapplied.PDF
10/21/2024  1:08 PM      1227518 D1_Protocol_2024-515689-15_Redacted.PDF
10/21/2024  1:08 PM      1244707 D1_Protocol_2024-515689-15_Unapplied.PDF
10/21/2024  1:08 PM       163070 D4_Patient facing documents_Dosing Diary_paper_CZ.PDF
10/21/2024  1:08 PM      1455202 E1_IB Pirtobrutinib.PDF
10/21/2024  1:09 PM      2389350 F1_ Marketing-importing authorization MIA ELECTS.PDF
10/21/2024  1:08 PM       122562 F1_ Marketing-importing authorization MIA Manufacturer 1.PDF
10/21/2024  1:08 PM       131102 F1_ Marketing-importing authorization MIA Manufacturer 2.PDF
10/21/2024  1:09 PM       123263 F1_ Marketing-importing authorization MIA Manufacturer 3.PDF
10/21/2024  1:09 PM       119480 F2_QP GMP declaration JZNX ELECTS.PDF
10/21/2024  1:09 PM       598463 G1_IMPD_E-S LY3527727 LOXO-305.PDF
10/21/2024  1:09 PM      1667910 J1_Label IMP 611743 L1 LY BTLE BK.PDF
10/21/2024  1:09 PM      1582068 J1_Label IMP 611744 L1 LY BTLE BK.PDF
10/21/2024  1:09 PM      1446685 J1_Label IMP 612110 L1 LY BTLE BK.PDF
10/21/2024  1:09 PM        60638 R1_Compliance on the collection and use of personal data.PDF
10/21/2024  1:07 PM        20129 Statement of Relationship Lilly Loxo.PDF